Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model

International Journal of Cancer

Volumn 129, Issue 7, 2011, Pages 1552-1563

  Shanmugam, Muthu K ^a   Manu, Kanjoormana A ^a   Ong, Tina H ^b   Ramachandran, Lalitha ^a   Surana, Rohit ^a,c   Bist, Pradeep ^d   Lim, Lina H K ^d   Prem Kumar, Alan ^a,c   Hui, Kam M ^b   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CXCR4; invasion; metastasis; prostate cancer; TRAMP; ursolic acid

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME INHIBITOR; URSOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISTANT METASTASIS; DOSE RESPONSE; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER METASTASIS; LUNG METASTASIS; LYSOSOME; MALE; METASTASIS INHIBITION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIME; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; VISCERAL METASTASIS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 79960897861     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26120     Document Type: Article

References (47)

1. Nguyen DX, Bos PD, Massague J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
2. Lazennec G, Richmond A,. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-44.
3. Aggarwal BB, Gehlot P,. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-69.
4. Kruizinga RC, Bestebroer J, Berghuis P, de Haas CJ, Links TP, de Vries EG, Walenkamp AM,. Role of chemokines and their receptors in cancer. Curr Pharm Des 2009; 15: 3396-416.
5. Teicher BA, Fricker SP,. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
6. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK,. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004; 23: 157-67. (Pubitemid 38142250)
7. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7. (Pubitemid 34408510)
8. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ,. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005; 23: 879-94. (Pubitemid 41170944)
9. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA,. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34: 70-4. (Pubitemid 36548793)
10. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T,. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-8. (Pubitemid 26268957)
11. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P,. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-65. (Pubitemid 27508828)
12. Singh S, Singh UP, Grizzle WE, Lillard JW, Jr,. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004; 84: 1666-76. (Pubitemid 39600573)
13. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML,. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48. (Pubitemid 43005947)
14. Gladson CL, Welch DR,. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 2008; 7: 1849-51.
15. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED,. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol 2001;Chapter 20:Unit 20 5.
16. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H,. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 2008; 99: 539-42. (Pubitemid 351228571)
17. Liu J,. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995; 49: 57-68. (Pubitemid 26010740)
18. Novotny L, Vachalkova A, Biggs D,. Ursolic acid: an anti-tumorigenic and chemopreventive activity. Minireview. Neoplasma 2001; 48: 241-6. (Pubitemid 32802432)
19. Liu J,. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005; 100: 92-4. (Pubitemid 41073528)
20. Ikeda Y, Murakami A, Ohigashi H,. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol Nutr Food Res 2008; 52: 26-42. (Pubitemid 351211800)
21. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB,. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 2003; 63: 4375-83. (Pubitemid 36951006)
22. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA,. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006; 78: 1784-93.
23. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB,. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 2007; 5: 943-55. (Pubitemid 47416671)
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-43.
25. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM,. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-91. (Pubitemid 27468967)
26. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R,. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68: 6822-30.
27. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A, Desai D, Amin S, et al,. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009; 69: 2117-25.
28. Chua AW, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, Koay ES, Lim LH, Kumar AP, Sethi G,. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kappaB activation in breast and pancreatic tumor cells. Biochem Pharmacol 2010; 80: 1553-62.
29. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G,. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 2010; 17: 1425-39.
30. Saccani S, Pantano S, Natoli G,. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 2002; 3: 69-75. (Pubitemid 34065620)
31. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC,. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-69. (Pubitemid 39469982)
32. Marchese A, Benovic JL,. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 2001; 276: 45509-12.
33. Bhandari D, Trejo J, Benovic JL, Marchese A,. Arrestin-2 interacts with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4. J Biol Chem 2007; 282: 36971-9.
34. Helbig G, Christopherson KW, 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H,. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003; 278: 21631-8. (Pubitemid 36792563)
35. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R,. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J Biol Chem 1999; 274: 19965-72. (Pubitemid 29327783)
36. Xing Y, Liu M, Du Y, Qu F, Li Y, Zhang Q, Xiao Y, Zhao J, Zeng F, Xiao C,. Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: a possible metastasis preventing and minimizing approach. Cancer Biol Ther 2008; 7: 1839-48.
37. Vindrieux D, Escobar P, Lazennec G,. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16: 663-73.
38. Murphy PM,. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001; 345: 833-5.
39. Proudfoot AE,. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-15. (Pubitemid 37323234)
40. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL,. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005; 65: 10355-62. (Pubitemid 41743728)
41. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ,. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100: 2597-606.
42. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W,. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425: 307-11. (Pubitemid 37158407)
43. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G, et al,. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-402. (Pubitemid 37392484)
44. Bachelder RE, Wendt MA, Mercurio AM,. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-6. (Pubitemid 36025239)
45. Benovic JL, Marchese A,. A new key in breast cancer metastasis. Cancer Cell 2004; 6: 429-30. (Pubitemid 39469976)
46. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR,. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007; 28: 123-31. (Pubitemid 46975998)
47. Sethi G, Tergaonkar V,. Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 2009; 30: 313-21.